High efficacy of chemoradiation therapy sensitized by weekly docetaxel for anaplastic thyroid cancer

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3445-3448

  Onoda, Naoyoshi ^a   Kashiwagi, Shinichiro ^a   Noda, Satoru ^a   Kawajiri, Hidemi ^a   Takashima, Tsutomu ^a   Ishikawa, Tetsuro ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaplastic thyroid carcinoma; Chemoradiation therapy; Docetaxel; Local control; Palliative management

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; SURVIVAL TIME; THYROID CARCINOMA; TREATMENT OUTCOME;

ANAPLASTIC THYROID CARCINOMA; CHEMORADIATION THERAPY; DOCETAXEL; LOCAL CONTROL; PALLIATIVE MANAGEMENT;

AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; TAXOIDS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84883293039     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Smallridge RC: Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 97: 2566-2572, 2012.
2. Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A and Suzuki S: Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36: 1247-1254, 2012.
3. Takami H, Ito Y, Noguchi H, Yoshida A, Okamoto T (eds.): Treatment of Thyroid Tumor. Japanese Clinical Guidelines. Springer Japan, Tokyo, pp. 203-227, 2013.
4. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce: American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22: 1104-1139, 2012.
5. http://www.nccn.org/professionals/physician-gls/pdf/thyroid.pdf
6. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7): vii110-19, 2012.
7. Perri F, Lorenzo GD, Scarpati GD and Buonerba C: Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol 2: 150-157, 2011.
8. Shaha AR: Airway management in anaplastic thyroid carcinoma. Laryngoscope 118: 1195-1198, 2008.
9. Lang BH and Lo CY: Surgical options in undifferentiated thyroid carcinoma. World J Surg 31: 969-977, 2007.
10. Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, Okami K, Inuyama Y; Japan Cooperative Head and Neck Oncology Group (JCHNOG): Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 9: 107-112, 2004.
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
12. National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 4.0. Lawrenceville, GA: DCTD, NCI, NIH, NHHS; May 28, 2009.
13. Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K and Ito K: Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21: 1183-1189, 2011.
14. Kebebew E, Greenspan FS, Clark OH, Woeber KA and McMillan A: Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103: 1330-1335, 2005.
15. Brierley JD and Tsang RW: External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 37: 497-509, xi, 2008.
16. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T and Brierley J: Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107: 1786-1792, 2006.
17. Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C and Newbold K: Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys 74: 518-521, 2009.
18. De Crevoisier R, Baudin E, Bachelot E, Leboulleux S, Travagli JP, Caillou B and Schlumberger M: Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60: 1137-1143, 2004.
19. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL and Wallin G: Anaplastic thyroid carcinoma: 3 protocols combining doxorubicin, hyperfractionated radiotherapy, and surgery. Br J Cancer 86: 1848-1853, 2002.
20. Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B and Raderer M: High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 95: E54-57, 2010.
21. Tanaka K, Sugitani I and Fujimoto Y: A novel chemoradiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. Jpn J Clin Oncol 41: 1074-1078, 2011.
22. Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, Matsuzuka F and Miyauchi A: Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20: 7-14, 2010.
23. Kawada K, Kitagawa K, Kamei S, Inada M, Mitsuma A, Sawaki M, Kikumori T, Fujimoto Y, Arima H, Imai T and Ando Y: The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 40: 596-599, 2010.
24. Rosove MH, Peddi PF and Glaspy JA: BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368: 684-685, 2013.